OP-1250 for Advanced Breast Cancer
(OPERA-01 Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that participants must have previously received a CDK4/6 inhibitor with endocrine therapy, so you might need to continue certain treatments. It's best to discuss your current medications with the trial team.
What data supports the effectiveness of the drug OP-1250 (Palazestrant) for advanced breast cancer?
Research shows that letrozole, a component of the treatment, is effective in treating advanced breast cancer, with studies indicating it is more effective than tamoxifen and anastrozole in certain cases. Letrozole has been shown to improve disease-free survival and has a higher overall response rate compared to anastrozole in advanced breast cancer.12345
What safety data exists for OP-1250 and related treatments in humans?
What makes OP-1250 (Palazestrant) unique compared to other breast cancer drugs?
OP-1250 (Palazestrant) is unique because it is a new type of drug being tested for advanced breast cancer, potentially offering a different mechanism of action compared to existing aromatase inhibitors like anastrozole, exemestane, and letrozole, which are already used for hormone receptor-positive breast cancer.268910
What is the purpose of this trial?
This trial is testing a new drug called palazestrant to see if it works better than current treatments for adults with advanced breast cancer that has not responded to previous therapies. The drug aims to stop cancer growth by blocking estrogen.
Research Team
Medical Director, MD
Principal Investigator
Olema Pharmaceuticals, Inc.
Eligibility Criteria
This trial is for adults with ER+/HER2- advanced breast cancer that's progressed after endocrine therapy and a CDK4/6 inhibitor. Participants need to be in good physical condition (ECOG 0 or 1), have proper organ function, and if male or pre-menopausal female, agree to take hormone-blocking injections.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose-Selection
Participants are randomized to one of the two doses of palazestrant or to the standard-of-care endocrine therapy to evaluate adverse events, drug discontinuation, and dose reduction
Treatment
Participants receive either palazestrant or standard-of-care endocrine therapy to compare overall survival and progression-free survival
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Anastrozole
- Exemestane
- Fulvestrant
- Letrozole
- OP-1250 (Palazestrant)
Anastrozole is already approved in European Union, United States, Canada, Japan for the following indications:
- Breast cancer
- Early breast cancer in postmenopausal women
- Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer
- First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer
- Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer
- Treatment of postmenopausal women with hormone receptor-positive advanced breast cancer
- Breast cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Olema Pharmaceuticals, Inc.
Lead Sponsor